Which medications in the drug class mTOr Kinase Inhibitor are used in the treatment of Renal Cell Carcinoma?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

mTOr Kinase Inhibitor

Temsirolimus (Torisel)

Temsirolimus is a water-soluble ester of sirolimus that binds with high affinity to immunophilin FKBP (FK506 binding protein) and is indicated for advanced renal cell carcinoma. This complex inhibits mammalian target of rapamycin (mTOR) kinase, a key protein in cells that regulates gene translation responsible for cell cycle regulation. mTOR also reduces cell growth factors (eg, vascular endothelial growth factor [VEGF]) involved in new blood vessel development.

Everolimus (Afinitor)

Everolimus is a rapamycin-derivative kinase inhibitor that is indicated for advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. This agent reduces cell proliferation and angiogenesis by inhibition of mTOR pathway.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!